Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
SBFM 
Sunshine Biopharma Inc (SBFM)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: SBFM (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $7
1 Year Target Price $7
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -40.97% | Avg. Invested days 33 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 6.88M USD | Price to earnings Ratio - | 1Y Target Price 7 |
Price to earnings Ratio - | 1Y Target Price 7 | ||
Volume (30-day avg) 1 | Beta 0.24 | 52 Weeks Range 1.17 - 3.75 | Updated Date 08/15/2025 |
52 Weeks Range 1.17 - 3.75 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -15.02 |
Earnings Date
Report Date 2025-08-14 | When - | Estimate -0.11 | Actual -0.39 |
Profitability
Profit Margin -17.35% | Operating Margin (TTM) -10.55% |
Management Effectiveness
Return on Assets (TTM) -11.18% | Return on Equity (TTM) -25.65% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -2483818 | Price to Sales(TTM) 0.19 |
Enterprise Value -2483818 | Price to Sales(TTM) 0.19 | ||
Enterprise Value to Revenue 0.01 | Enterprise Value to EBITDA -7.73 | Shares Outstanding 4555940 | Shares Floating 4553895 |
Shares Outstanding 4555940 | Shares Floating 4553895 | ||
Percent Insiders 3.17 | Percent Institutions 1.85 |
Upturn AI SWOT
Sunshine Biopharma Inc
Company Overview
History and Background
Sunshine Biopharma Inc. was founded in 2006. The company focuses on the research, development, and commercialization of oncology and antiviral drugs. Significant milestones include advancing certain drug candidates through preclinical and clinical trials.
Core Business Areas
- Pharmaceutical Development: Focuses on the development and commercialization of oncology and antiviral drugs.
- Drug Research: Conducting research to discover and develop novel therapeutic agents.
Leadership and Structure
The leadership team consists of key executives overseeing various aspects of the company's operations, including research, development, and finance. The organizational structure is typical for a biotechnology company.
Top Products and Market Share
Key Offerings
- Adva-27a: Adva-27a is a proprietary anticancer compound being developed for various cancer indications. No significant market share or revenue data available. Competitors include companies developing similar chemotherapeutic agents.
- mRNA Drug Program: Sunshine Biopharma is developing mRNA-based therapeutics. Market share and revenue data are not publicly available. Competitors include companies focused on mRNA therapeutics, such as Moderna and BioNTech.
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive and regulated, with significant investment in research and development. It includes segments such as oncology, antiviral therapies, and mRNA therapeutics.
Positioning
Sunshine Biopharma Inc. is a small player within the larger pharmaceutical industry, focusing on niche markets. Its competitive advantage lies in its proprietary drug candidates.
Total Addressable Market (TAM)
The oncology and antiviral therapeutics market are multi-billion dollar markets. Sunshine Biopharma's TAM is based on potential addressable populations for their drug candidates. Significant development and regulatory hurdles exist to fully address this TAM.
Upturn SWOT Analysis
Strengths
- Proprietary drug candidates
- Focus on niche markets
- Experienced leadership team
Weaknesses
- Limited financial resources
- Early stage of development
- High dependence on successful clinical trials
Opportunities
- Partnerships and collaborations
- Expansion into new markets
- Successful clinical trial outcomes
Threats
- Competition from larger pharmaceutical companies
- Regulatory hurdles
- Failure in clinical trials
Competitors and Market Share
Key Competitors
- MRNA
- BNTX
- JNJ
Competitive Landscape
Sunshine Biopharma faces intense competition from larger, more established pharmaceutical companies with significantly more resources. The company's success depends on differentiating its drug candidates and securing partnerships.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is difficult to assess without detailed financial data. Please refer to financial statements in Sunshine Biopharma's filings.
Future Projections: Future growth depends on successful clinical trials and regulatory approvals. Analyst estimates are limited due to the early stage of development.
Recent Initiatives: Recent initiatives include advancing Adva-27a through clinical trials and developing mRNA therapeutics.
Summary
Sunshine Biopharma Inc. is a small biotechnology company focusing on the development of novel oncology and antiviral drugs. The company's success hinges on the successful clinical development and regulatory approval of its drug candidates. Limited financial resources and intense competition pose significant challenges. Securing partnerships and collaborations is crucial for future growth and sustainability.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Yahoo Finance
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a financial professional.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Sunshine Biopharma Inc
Exchange NASDAQ | Headquaters Fort Lauderdale, FL, United States | ||
IPO Launch date 2009-10-30 | Chairman, President & CEO Dr. Steve N. Slilaty Ph.D. | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 52 | Website https://sunshinebiopharma.com |
Full time employees 52 | Website https://sunshinebiopharma.com | ||
Sunshine Biopharma, Inc. operates as a pharmaceutical company that focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates through Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products segments. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; Adva-27a, a small chemotherapy molecule to treat pancreatic cancer; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurine products. In addition, the company provides various generic prescription drugs for osteoporosis, cardiovascular, antipsychotic, antibacterial, hypertension, anti-inflammatory, allergy, antibiotic, central nervous system, diabetes, urology, antifungal, antimalarial, oncology, gastroenterology, and anticonvulsant indications. Sunshine The company is based in Fort Lauderdale, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.